Azelastine and Etodolac drug interactions - a phase IV clinical study of FDA data

Summary:

Drug interactions are reported among people who take Azelastine (azelastine hydrochloride) and Etodolac (etodolac). Common drug interactions include hospitalisation among females and chronic kidney disease among males.

The phase IV clinical study analyzes what interactions people have when they take Azelastine and Etodolac. It is created by eHealthMe based on reports of 55 people who take the same drugs from the FDA, and is updated regularly.

What is Azelastine?

Azelastine has active ingredients of azelastine hydrochloride. It is often used in allergies. eHealthMe is studying from 17,400 Azelastine users. Check the latest studies of Azelastine.

What is Etodolac?

Etodolac has active ingredients of etodolac. It is often used in arthritis. eHealthMe is studying from 9,157 Etodolac users. Check the latest studies of Etodolac.



On Jul, 11, 2026

55 people who take Azelastine and Etodolac together, and have interactions are studied.

Azelastine and Etodolac drug interactions.

What are the common drug interactions of Azelastine and Etodolac, by gender? *:

female:

  1. Hospitalisation
  2. Hyperkalaemia (damage to or disease of the kidney)
  3. Hypersensitivity
  4. Hypoaesthesia (reduced sense of touch or sensation)
  5. Hypoxia (low oxygen in tissues)
  6. Fatigue (feeling of tiredness)
  7. Drug ineffective
  8. Abdominal pain
  9. Cough
  10. Loss of consciousness

male:

  1. Chronic kidney disease
  2. Renal failure (kidney dysfunction)
  3. Malignant melanoma (skin cancer rises from melancytes)
  4. Musculoskeletal stiffness (stiffness of the body's muscles, joints, tendons, ligaments and nerves)
  5. Nephrogenic anaemia (anaemia due to kidney disease)
  6. Nephropathy (damage to or disease of a kidney)
  7. On and off phenomenon
  8. Pruritus (severe itching of the skin)
  9. Renal disorder (kidney disease)
  10. Renal impairment (severely reduced kidney function)

What are the common drug interactions of Azelastine and Etodolac, by age (0-1 to 60+)? *:

0-1:

n/a

2-9:

n/a

10-19:

n/a

20-29:

n/a

30-39:

  1. Autonomic nervous system imbalance (autonomic nervous system is of net equal emphasis)
  2. Pruritus (severe itching of the skin)

40-49:

  1. Amnesia (deficit in memory caused by brain damage, disease, or psychological trauma)
  2. Arthropod sting (arthropod bite)
  3. Benign neoplasm of thyroid gland (benign (non-cancerous) tumours of the thyroid gland)
  4. Bronchitis (inflammation of the mucous membrane in the bronchial tubes)
  5. Cellulitis (infection under the skin)
  6. Confusional state
  7. Diarrhoea
  8. Dizziness
  9. Drug ineffective
  10. Fall

50-59:

  1. Chronic kidney disease
  2. Asthma
  3. Anhedonia (inability to experience pleasure from activities usually found enjoyable)
  4. Anxiety
  5. Depression
  6. Drug ineffective
  7. Emotional distress
  8. Gastrooesophageal reflux disease (stomach contents (food or liquid) leak backwards from the stomach into the oesophagus)
  9. Haematochezia (passage of stools containing blood)
  10. Hospitalisation

60+:

  1. Fatigue (feeling of tiredness)
  2. Bronchitis (inflammation of the mucous membrane in the bronchial tubes)
  3. Drug ineffective
  4. Loss of consciousness
  5. Stomatitis (inflammation of mucous membrane of mouth)
  6. Breast cancer female
  7. Abdominal pain
  8. Arthralgia (joint pain)
  9. Dry eye (lack of adequate tears)
  10. Ear disorder

What are the existing conditions these people have? *

  1. Rheumatoid Arthritis (a chronic progressive disease causing inflammation in the joints): 11 people, 20.00%
  2. Pain: 9 people, 16.36%
  3. High Blood Pressure: 8 people, 14.55%
  4. Gastroesophageal Reflux Disease (a condition in which stomach contents leak backward from the stomach into the oesophagus): 8 people, 14.55%
  5. Immunodeficiency Common Variable: 7 people, 12.73%
  6. Narcolepsy (brain's inability to regulate sleep-wake cycles normally): 6 people, 10.91%
  7. Nausea (feeling of having an urge to vomit): 5 people, 9.09%
  8. Asthma: 5 people, 9.09%
  9. Primary Immunodeficiency Syndrome: 4 people, 7.27%
  10. Hypersensitivity: 4 people, 7.27%

* Approximation only. Some reports may have incomplete information.

Do you take Azelastine and Etodolac?

- Personalize this study to your gender, age, symptoms and drugs
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously



Related studies:

Effectiveness of, side effects of, and alternative drugs to the 2 drugs:

Browse all drug interactions of Azelastine and Etodolac:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Sub-studies by gender and age:

Female: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Male: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Browse all side effects of Azelastine:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all side effects of Etodolac:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all interactions between Azelastine and drugs from A to Z:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all interactions between Etodolac and drugs from A to Z:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Related publications that referenced our studies


How the study uses the data?

The study uses data from the FDA. It is based on azelastine hydrochloride and etodolac (the active ingredients of Azelastine and Etodolac, respectively), and Azelastine and Etodolac (the brand names). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.



Recent studies on eHealthMe: